Printer Friendly

Browse Biotechnology industries topic

Product development subtopic

Articles

1-300 out of 600 article(s) nextnext page
Title Author Type Date Words
Phase III Clinical Study of Valbenazine for Chorea in Huntington Disease. Clinical report Nov 14, 2019 573
Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting. Nov 12, 2019 498
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study. Nov 12, 2019 672
Aptevo Therapeutics and Alligator Bioscience to present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting. Nov 11, 2019 360
Aptevo Therapeutics and Alligator Bioscience to present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting. Nov 11, 2019 356
United States : PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product. Nov 11, 2019 426
United States : Exelixis Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy. Nov 8, 2019 608
PharmaCyte Biotech Closer to Submitting IND by Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product. Nov 7, 2019 608
Active Biotech announces presentation of new preclinical data on naptumomab estafenatox at the Society for Immunotherapy of Cancer's 34th Annual Meeting. Nov 6, 2019 243
Active Biotech announces presentation of new preclinical data on naptumomab estafenatox at the Society for Immunotherapy of Cancer's 34th Annual Meeting. Nov 6, 2019 239
Compugen receives FDA clearance of IND application for COM902 in patients with advanced malignancies. Nov 5, 2019 234
Compugen receives FDA clearance of IND application for COM902 in patients with advanced malignancies. Nov 5, 2019 230
US FDA Grants Fast Track Designation to BNC210 Development Programme for the Treatment of PTSD. Nov 5, 2019 239
Bionomics receives Fast Track Designation grant from US FDA for BNC210 development program for PTSD treatment. Nov 4, 2019 349
Bionomics receives Fast Track Designation grant from US FDA for BNC210 development program for PTSD treatment. Nov 4, 2019 345
Krystal Biotech to initiate manufacturing of Phase 3 clinical material in Nov. Nov 4, 2019 205
ACADIA Pharmaceuticals starts phase three LAVENDER placebo-controlled study to assess Trofinetide. Clinical report Nov 1, 2019 263
ACADIA Pharmaceuticals starts phase three LAVENDER placebo-controlled study to assess Trofinetide. Clinical report Nov 1, 2019 259
Themis Bioscience starts phase 1 trial of MV-LASV. Oct 31, 2019 168
Themis Bioscience starts phase 1 trial of MV-LASV. Oct 31, 2019 164
Themis Bioscience, CEPI Announce Start Phase 1 Clinical Trial with Lassa Fever Vaccine. Oct 31, 2019 741
Acadia initiates Phase 3 pivotal study of trofinetide. Oct 30, 2019 140
MaxCyte phase drug making "significant progress". Oct 25, 2019 298
MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials. Oct 25, 2019 134
MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials. Oct 25, 2019 132
Genentech Touts Phase III PEMPHIX Study Results Showing Rituxan Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris. Clinical report Oct 23, 2019 133
Preliminary PEC-Direct Clinical Data Presented: Insulin Production From Stem Cell-Derived Islet Replacement Therapy. Oct 21, 2019 322
ArQule announces preclinical data showing potential for miransertib to treat VMs. Oct 21, 2019 210
GlaxoSmithKline (LSE: GSK) - GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies -- 8/10/2019. Oct 15, 2019 697
I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy. Oct 14, 2019 251
I-Mab to expand ongoing phase II and III clinical trials of TJ202/MOR202 into China under fast-to-market development strategy. Oct 14, 2019 247
MorphoSys, I-Mab Biopharma announce IND approval to initiate trials. Oct 14, 2019 197
Adverum Biotechnologies reports additional data from Phase 1 trial of ADVM-022. Oct 13, 2019 474
Acadia Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress. Oct 11, 2019 343
Advaxis Releases Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial. Oct 11, 2019 509
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies. Oct 9, 2019 1345
Calithera Biosciences completes patient enrollment in CANTATA trial. Oct 3, 2019 202
Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer. Oct 2, 2019 822
Five Prime Therapeutics Presents Updated Data from the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress. Oct 2, 2019 436
Japan Pharmaceuticals Industry - Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer -- 28/9/2019. Oct 2, 2019 1246
Seattle Genetics (NASDAQ: SGEN) - Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer -- 29/9/2019. Oct 2, 2019 405
Zealand Pharma reports positive results in paediatric Phase 3 trial with dasiglucagon for severe hypoglycaemia. Sep 25, 2019 236
Zealand Pharma reports positive results in paediatric Phase 3 trial with dasiglucagon for severe hypoglycaemia. Sep 25, 2019 232
Bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy at the 13th European Pediatric Neurology Society Congress. Clinical report Sep 24, 2019 702
Alnylam Pharmaceuticals starts APOLLO-B trial of Patisiran. Sep 18, 2019 152
Precision BioSciences announces FDA clearance of IND for PBCAR20A. Sep 16, 2019 110
Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact with an Infected Person by 86%. Sep 5, 2019 111
Genentech Presents Positive Phase III Study Results for One-dose Xofluza in Children with the Flu. Clinical report Sep 3, 2019 765
Intra-Cellular Therapies, Inc. achieved top-line results from two Phase III trials (Study 401 and Study 404) evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Sep 1, 2019 223
CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program. Aug 22, 2019 1461
Cytokinetics announces preclinical data for CK-3773274. Jul 31, 2019 329
Elon Musk reveals brain-hacking plans. Jul 28, 2019 105
Acadia Pharmaceuticals reveals top-line results from Pimavanserin Phase three enhance study. Jul 24, 2019 253
Acadia Pharmaceuticals reveals top-line results from Pimavanserin Phase three enhance study. Jul 24, 2019 249
Cytokinetics announces publication of preclinical data on FTSA. Jul 24, 2019 289
Anixa Biosciences CEO expects IND filing in ovarian cancer by year-end. Jul 24, 2019 324
Acadia Pharmaceuticals Releases Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia. Jul 23, 2019 739
United States : New Immune Data From Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential For Neoantigen-Directed Immunotherapies. Jul 20, 2019 908
Elon Musk's Neuralink plans to build brain-reading implants. Jul 18, 2019 478
New Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed Immunotherapies. Jul 16, 2019 903
Advaxis to Increase Focus on Neoantigen-Directed Immunotherapies, Closes Phase 3 AIM2CERV Study. Jun 28, 2019 400
Alligator Bioscience announces submission of clinical trial authorisation application for ATOR-1017. Jun 19, 2019 225
Alligator Bioscience applies for phase one clinical trial authorisation for ATOR-1017. Jun 19, 2019 159
Alligator Bioscience announces submission of clinical trial authorisation application for ATOR-1017. Jun 19, 2019 221
Alligator Bioscience applies for phase one clinical trial authorisation for ATOR-1017. Jun 19, 2019 155
ArQule Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies. Jun 18, 2019 419
ArQule announces preliminary results from phase 1 ARQ 531 study at EHA. Jun 14, 2019 253
Genentech Touts Positive Topline Results for Gazyva in Phase II Lupus Nephritis Study. Jun 12, 2019 532
Genentech Presents Pivotal Phase III CLL14 Results for Venclexta in Combination with Gazyva for Chronic Lymphocytic Leukemia. Jun 6, 2019 115
Seattle Genetics (NASDAQ: SGEN) - Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS[R] (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting -- 3/6/2019. Jun 6, 2019 1242
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer. Jun 4, 2019 870
Acadia presents Phase 2 CLARITY results for Pimavanserin. Clinical report May 19, 2019 315
Alligator Bioscience announces that data of ADC-1013 from phase I clinical trial will be presented at ASCO. May 16, 2019 303
Alligator Bioscience announces that data of ADC-1013 from phase I clinical trial will be presented at ASCO. May 16, 2019 299
PharmaCyte Biotech Advances Manufacturing Process for Clinical Trial in Pancreatic Cancer. May 9, 2019 699
PharmaCyte Biotech advances manufacturing process for pancreatic cancer product used in clinical trial. May 8, 2019 163
PharmaCyte Biotech advances manufacturing process for pancreatic cancer product used in clinical trial. May 8, 2019 159
Sinovant Sciences' Derazantinib's Clinical Trial Application Approved by the China National Medical Products Administration. May 2, 2019 458
Sinovant announces China approval of derazantinib's clinical trial application. Apr 30, 2019 101
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria. Apr 17, 2019 1081
Moleculin Biotech signs drug trial contract with Emory University. Apr 12, 2019 104
Puma Biotechnology expands two additional cohorts for Neratinib Phase II clinical trial. Apr 8, 2019 182
Puma Biotechnology expands two additional cohorts for Neratinib Phase II clinical trial. Apr 8, 2019 178
United States : Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinsons Disease in the Annals of Neurology. Apr 3, 2019 184
Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer. Apr 2, 2019 526
Seattle Genetics and Astellas Tout Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer. Apr 1, 2019 731
Seattle Genetics and Astellas announce positive top-line results from enfortumab vedotin cancer trial. Mar 29, 2019 291
Seattle Genetics and Astellas announce positive top-line results from enfortumab vedotin cancer trial. Mar 29, 2019 287
Acadia says Phase 2 Trofinetide results published in Neurology. Clinical report Mar 27, 2019 244
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer. Mar 21, 2019 497
MorphoSys--MorphoSys AG: MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL--7/3/2019. Mar 20, 2019 547
Alligator Bioscience to present new preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, London. Mar 19, 2019 236
MorphoSys, I-Mab Biopharma initiate phase 2 study of TJ202 for multiple myeloma. Mar 19, 2019 118
United States : Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia. Mar 13, 2019 493
Alnylam Touts Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria. Mar 8, 2019 929
Results From French Clinical Trial Of Cell Therapy In Crohn's Disease. Feb 25, 2019 512
Advaxis Enrolls First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer. Feb 19, 2019 413
FDA Clears IND Application For Therapy Derived From Engineered Stem Cells. Feb 18, 2019 444
Clinical Trial Results For Cell Therapy In Crohn's Disease. Feb 18, 2019 509
FDA Clears IND Application For Therapy Derived From Engineered Stem Cells. Feb 18, 2019 444
Clinical Trial Results For Cell Therapy In Crohn's Disease. Feb 18, 2019 509
Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts. Feb 14, 2019 276
Alnylam's Phase 1 Givosiran Data Published in The New England Journal of Medicine. Feb 8, 2019 1411
Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer. Jan 30, 2019 245
Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer. Jan 30, 2019 246
Cantargia reports treatment of first patient with antibody CAN04 in the phase IIa part of CANFOUR trial. Jan 28, 2019 335
ViaCyte & Center for Beta Cell Therapy in Diabetes partnership begins clinical trial of human stem cell-derived implants in Type 1 diabetes patients in Europe. Jan 22, 2019 277
ViaCyte & Center for Beta Cell Therapy in Diabetes partnership begins clinical trial of human stem cell-derived implants in Type 1 diabetes patients in Europe. Jan 22, 2019 273
Seattle Genetics Data Published On North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of Adcetris in Newly Diagnosed Advanced Hodgkin Lymphoma. Jan 11, 2019 752
Basilea Touts Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma. Jan 10, 2019 798
Onxeo has identified predictive biomarkers for AsiDNA. Jan 4, 2019 316
BerGenBio announces first patient dosing in phase II investigator initiated trial evaluating selective AXL inhibitor bemcentinib in high-risk MDS. Brief article Jan 4, 2019 285
United States : Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas. Dec 8, 2018 715
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit. Dec 6, 2018 1003
Blaze Bioscience Initiates Pivotal Clinical Trial for Tumor Paint: BLZ-100 and the Canvas Imaging System. Dec 5, 2018 455
FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain. Dec 4, 2018 457
AbbVie presents new data from Phase 3 MURANO trial of VENCLEXTA/VENCLYXTO. Dec 2, 2018 397
Potential for Natural Health Products in Canada Shifting into High Gear: Demand for natural, clean label, healthy products has taken hold in Canada. Investment and commercialization resources are keeping pace. King, Shelley Dec 1, 2018 930
Generex Biotechnology Signs Clinical Trial Agreement with the NSABP Foundation for Phase II Clinical Trial of AE37 in Combination with Pembrolizumab for Treatment of Triple-Negative Breast Cancer. Nov 29, 2018 433
Positive Preliminary Results From Australian Parkinson's Trial. Nov 19, 2018 538
United States : Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-BCMA for Patients with Relapsed or Refractory Multiple Myeloma. Nov 17, 2018 288
ArQule presents clinical, preclinical data for ARQ 751. Nov 16, 2018 256
Positive Preliminary Results From Australian Parkinson's Trial. Nov 12, 2018 538
Positive Preliminary Results From Australian Parkinson's Trial. Nov 12, 2018 538
Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet. Nov 8, 2018 488
Acadia reports Phase 2 CLARITY trial in MDD met primary endpoint. Oct 31, 2018 252
ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. Oct 15, 2018 390
ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. Oct 15, 2018 389
Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. Oct 9, 2018 537
United States : Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. Financial report Oct 6, 2018 716
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1. Clinical report Oct 5, 2018 1181
Alnylam Submits Clinical Trial Authorization Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. Oct 4, 2018 437
Seattle Genetics, Takeda Tout Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating Adcetris in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. Oct 2, 2018 1050
Intra-Cellular Therapies submits NDA for new schizophrenia treatment. Sep 28, 2018 142
Intra-Cellular Therapies submits NDA for new schizophrenia treatment. Sep 28, 2018 138
AmpliPhi Biosciences Claims Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01. Sep 18, 2018 600
Active Biotech to present data from the phase 2 LEGATO-HD study of laquinimod in Huntington's disease at EHDN plenary meeting 2018 in Vienna. Sep 14, 2018 230
Active Biotech to present data from the phase 2 LEGATO-HD study of laquinimod in Huntington's disease at EHDN plenary meeting 2018 in Vienna. Sep 14, 2018 231
Acadia publishes additional data from Phase 2 study of pimavanserin. Clinical report Sep 10, 2018 387
Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine. Aug 31, 2018 139
Imago BioSciences Completes Enrollment in Phase 1/2a Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Report Aug 23, 2018 320
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias. Aug 23, 2018 1107
Izana Bioscience commenced phase II proof-of-concept clinical study of ankylosing spondylitis drug namilumab. Clinical report Aug 15, 2018 163
Izana Bioscience commenced phase II proof-of-concept clinical study of ankylosing spondylitis drug namilumab. Clinical report Aug 15, 2018 159
Izana Bioscience Initiates Namilumab Phase II Proof-of-Concept Clinical Study in Ankylosing Spondylitis. Clinical report Aug 15, 2018 333
ArQule announces publication of ARQ531 preclinical data. Aug 13, 2018 138
Proclara Biosciences Initiates Clinical Trial of NPT189 for Systemic Amyloidoses. Jul 31, 2018 175
JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma. Jul 31, 2018 276
SOM Biotech Commences Phase 2a Clinical Trial of SOM3355 in Huntington's Disease. Jul 20, 2018 366
Roche succeeds in phase three flu study of baloxavir marboxil. Jul 19, 2018 301
Roche succeeds in phase three flu study of baloxavir marboxil. Jul 19, 2018 297
Fat-Derived Cell Therapy Snown Safe, Effective In ED Trial. Jul 16, 2018 276
United States : Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer. Financial report Jul 13, 2018 873
United States : Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors. Jul 13, 2018 317
Onxeo reports new preclinical results on AsiDNA. Brief article Jul 13, 2018 263
Progress Updated in Clinical Trials of Enfortumab Vedotin for Urothelial Cancer. Jul 13, 2018 323
Former Pacific Biosciences employee charged with insider trading. Jul 10, 2018 262
Fat-Derived Cell Therapy Shown Safe, Effective In ED Trial. Jul 9, 2018 276
Fat-Derived Cell Therapy Shown Safe, Effective In ED Trial. Jul 9, 2018 268
Genentech's Phase 3 Trial of Tecentric Combination Reduces Risk of Disease Progression in TNBC. Jul 9, 2018 218
JHL Biotech's Phase I and Phase III Clinical Trial Application for JHL1101 receives approval. Jul 6, 2018 132
JHL Biotech's Phase I and Phase III Clinical Trial Application for JHL1101 receives approval. Jul 6, 2018 128
Compugen reports FDA clearance of Bayer's IND application for BAY 1905254. Jul 2, 2018 203
Positive Two-Year Safety Data From Diabetes Clinical Trial. Jul 2, 2018 281
First Patient Of Third Cohort Dosed In Parkinson's Trial. Jul 2, 2018 679
Kymab and Roche sign clinical trial agreement. Jun 28, 2018 194
Kymab and Roche sign clinical trial agreement. Jun 28, 2018 190
Positive Two-Year Safety Data From Diabetes Trial Presented. Jun 25, 2018 281
ISCO Doses First Patient Of Third Cohort In Parkinson's Clinical Trial. Jun 25, 2018 680
Positive Two-Year Safety Data From Diabetes Trial Presented. Jun 25, 2018 281
ISCO Doses First Patient Of Third Cohort In Parkinson's Clinical Trial. Jun 25, 2018 680
Alligator Bioscience to present additional pre-clinical data for its candidate ATOR-1017 at World Preclinical Congress, Boston, US. Jun 22, 2018 247
Seattle Genetics Begins Phase 2 Trial of Tisotumab Vedotin in Cervical Cancer Patients. Jun 19, 2018 273
United States : Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer. Jun 18, 2018 445
First Patient Dosed in Investigational Personalized Neoantigen Immunotherapy Trial with ADXS-NEO. Jun 13, 2018 288
Syndax, Nektar Therapeutics Collaborate on Immuno-Oncology Clinical Trial. Jun 4, 2018 307
Roche announced results from Phase III IMpower131 study. Jun 3, 2018 118
US FDA Accepts IND from Turnstone Biologics for Immunotherapy Targeting HPV Positive Cancers. May 22, 2018 268
Adverum Biotechnologies presents ADVM-022 preclinical data at ASGCT. May 17, 2018 153
Dare Bioscience announces trial initiation for Ovaprene. May 15, 2018 187
Alnylam Preclinical Data Demonstrate CNS Delivery of RNAi Therapeutics. May 10, 2018 258
Alligator Bioscience to present pre-clinical data for ATOR-1017 at PEGS in Boston. May 4, 2018 165
Alligator Bioscience to present pre-clinical data for ATOR-1017 at PEGS in Boston. May 4, 2018 166
Alligator Bioscience to present pre-clinical data for ATOR-1017 at PEGS in Boston. May 4, 2018 161
Galapagos NV announces initiation of MOR 106 Phase 2 trial. Clinical report May 1, 2018 134
Kineta, Roche enter exclusive chronic pain development pact. May 1, 2018 290
Ablynx completes patient recruitment in Phase IIb RESPIRE study of ALX-0171. Apr 30, 2018 189
Ablynx completes patient recruitment in Phase IIb RESPIRE study of ALX-0171. Apr 30, 2018 185
Advaxis Presents Preclinical Data on Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types at The AACR Annual Meeting. Apr 19, 2018 269
Alligator Bioscience announces presentation ATOR-1015 preclinical data at the AACR Annual Meeting 2018. Apr 18, 2018 244
Alligator Bioscience announces presentation ATOR-1015 preclinical data at the AACR Annual Meeting 2018. Apr 18, 2018 240
Last Patients Enrolled In Trial Of Treatment For Stress Urinary Incontinence. Apr 9, 2018 281
Enrollment Completed In Trial Of Treatment For Stress Urinary Incontinence. Apr 2, 2018 284
Enrollment Completed In Trial Of Treatment For Stress Urinary Incontinence. Apr 2, 2018 284
Armo BioSciences completes first interim analysis in Phase 3 SEQUOIA study. Mar 26, 2018 255
FDA Places Advaxis Phase 1/2 Combination Study of Axalimogene Filolisbac with Imfinzi on Clinical Hold. Mar 13, 2018 257
Dosing Of Second Cohort In Parkinson's Trial Completed. Clinical report Mar 12, 2018 652
United States : AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model. Mar 10, 2018 267
ISCO Completes Dosing Of Second Cohort In Parkinson's Trial. Clinical report Mar 5, 2018 652
ISCO Completes Dosing Of Second Cohort In Parkinson's Trial. Clinical report Mar 5, 2018 651
Ablynx initiates dosing in Phase II study of ALX-0171. Clinical report Mar 2, 2018 190
Ablynx initiates dosing in Phase II study of ALX-0171. Clinical report Mar 2, 2018 186
FDA Grants Clearance to Intralytix to Begin Phase I / IIa Clinical Trials. Feb 20, 2018 265
Neurocrine Biosciences submits NDA for opicapone for Parkinson's disease based on existing pivotal clinical trial data. Feb 15, 2018 268
Neurocrine Biosciences submits NDA for opicapone for Parkinson's disease based on existing pivotal clinical trial data. Feb 15, 2018 264
FDA Accepts Alnylam NDA, Grants Priority Review Status for Patisiran for Treatment of Hereditary ATTR Amyloidosis. Feb 6, 2018 258
Imago BioSciences passes US FDA's approval of IND Application of IMG-7289 for Myeloid Malignancies. Feb 2, 2018 219
Imago BioSciences passes US FDA's approval of IND Application of IMG-7289 for Myeloid Malignancies. Feb 2, 2018 215
US FDA Accepts Asana BioSciences IND Application for Oral ERK1/2 Inhibitor. Jan 5, 2018 197
JHL Biotech submits clinical trial application to Bulgarian Drug Agency for proposed bevacizumab biosimilar for multiple cancers. Dec 21, 2017 169
JHL Biotech submits clinical trial application to Bulgarian Drug Agency for proposed bevacizumab biosimilar for multiple cancers. Dec 21, 2017 165
Aura Biosciences Preclinical Data Support Anti-cancer Activity of AU-011 in Ocular Melanoma. Dec 15, 2017 333
United Kingdom : Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma. Dec 11, 2017 884
Genetech shares positive results from Phase III HAVEN 4 study for Hemlibra prophylaxis. Dec 7, 2017 248
Genetech shares positive results from Phase III HAVEN 4 study for Hemlibra prophylaxis. Dec 7, 2017 244
Parkinson's Clinical Trial Yields Positive Interim Results. Clinical report Nov 20, 2017 493
Initial Results of Dose-escalation Phase of Trial of NKTR-214 in Combination with OPDIVO (nivolumab) Presented at SITC 2017. Nov 13, 2017 328
Seattle Genetics and Astellas Pharma Begin Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitors in Urothelial Cancer. Nov 9, 2017 335
Wave Life Sciences Commences Clinical Trial of WVE-210201 in Boys 5 to 18 Years Old with Duchenne Muscular Dystrophy. Clinical report Nov 7, 2017 394
Acadia Pharmaceuticals Phase II Study of Pimavanserin in Alzheimer's Disease Meets Primary Endpoint of Psychosis Reduction. Clinical report Nov 6, 2017 252
Hydra Biosciences and Boehringer Ingelheim Collaboration Initiates Clinical Trial of TRPC4/5 Inhibitor for CNS Disorders. Nov 3, 2017 244
United States : AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain. Nov 2, 2017 651
United Kingdom,United States : Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA (abatacept). Nov 2, 2017 183
Neurocrine begins Phase IIb clinical study of INGREZZA in children and adolescents with Tourette Syndrome. Oct 26, 2017 285
Neurocrine begins Phase IIb clinical study of INGREZZA in children and adolescents with Tourette Syndrome. Oct 26, 2017 281
Janssen Biotech submits NDA with the US FDA for apalutamide for non-metastatic castration-resistant prostate cancer. Oct 12, 2017 244
Janssen Biotech submits NDA with the US FDA for apalutamide for non-metastatic castration-resistant prostate cancer. Oct 12, 2017 240
Grant To Fund Clinical Trial Of Diabetes Therapy. Oct 9, 2017 377
TiGenix to present data from ADMIRE-CD Phase III clinical trial of Cx601. Oct 5, 2017 181
Saniona receives research milestone of USD119,487 from The Michael J Fox Foundation for Parkinson's research. Brief article Oct 4, 2017 229
Japan : Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Oct 4, 2017 633
Ablynx sees positive results from Phase III HERCULES study of caplacizumab. Oct 2, 2017 219
Ablynx sees positive results from Phase III HERCULES study of caplacizumab. Oct 2, 2017 215
Nerve regrowth. Brief article Oct 1, 2017 153
ViaCyte wins CIRM grant in support of clinical trial of PEC-Direct product candidate for high-risk type 1 diabetes. Sep 29, 2017 268
Alligator Bioscience announces presentation of ADC-1013 intratumoural clinical phase I study results at SITC in November 2017. Sep 22, 2017 255
Sanofi and Alnylam report topline results of patisiran in ATTR amyloidosis. Brief article Sep 20, 2017 163
Armo BioSciences Presents Additional Data from AM0010 Trials at ESMO 2017 Congress. Sep 11, 2017 425
Bolder BioTechnology Begins Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome. Aug 3, 2017 237
Adaptive Biotechnologies' immunoSEQ Platform to be Used in NCI-sponsored Clinical Trials. Jul 27, 2017 261
Ablynx and Sanofi enter strategic collaboration to develop Nanobody product candidates. Jul 20, 2017 236
Ablynx and Sanofi enter strategic collaboration to develop Nanobody product candidates. Jul 20, 2017 232
Imago BioSciences Begins Phase 2a of Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Jul 20, 2017 219
Nektar Presents Preclinical Data for Regulatory T Cell Stimulator at 13th World Congress of Inflammation. Jul 12, 2017 420
Alnylam Pharmaceuticals and Sanofi Genzyme start Atlas Phase three clinical programme for Fitusiran. Jul 11, 2017 258
IDSMB gives positive review for Neovacs' Phase IIb clinical trial of IFNalpha Kinoid in lupus. Jul 11, 2017 198
Alnylam Pharmaceuticals and Sanofi Genzyme start Atlas Phase three clinical programme for Fitusiran. Jul 11, 2017 262
IDSMB gives positive review for Neovacs' Phase IIb clinical trial of IFNalpha Kinoid in lupus. Jul 11, 2017 202
FDA Accepts Icon Bioscience NDA Filing for Dexycu for Treatment of Inflammation Associated with Cataract Surgery. Jun 27, 2017 297
Cytori to conduct burn clinical trial under HHS contract. Jun 12, 2017 851
Cytori to conduct burn clinical trial under HHS contract. Jun 12, 2017 851
Japan : Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma. Jun 10, 2017 420
Immunocore announces positive phase I data for its lead programme, IMCgp100. Jun 5, 2017 259
Immunocore announces positive phase I data for its lead programme, IMCgp100. Jun 5, 2017 255
Asana BioSciences Starts Phase 2 Evaluation of ASN002 in NHL, CLL and MF. May 31, 2017 241
TaiGen Biotechnology submits NDA for Taigexyn Intravenous Formulation the China FDA. May 30, 2017 201
TaiGen Biotechnology submits NDA for Taigexyn Intravenous Formulation the China FDA. May 30, 2017 197
ISCO completes first cohort in Parkinson's disease clinical trial. May 29, 2017 599
ISCO completes first cohort in parkinson's disease clinical trial. May 29, 2017 577
United States : Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac. May 16, 2017 411
S&W signs alfalfa seed development agreement with Generic Genetics. May 10, 2017 223
Austria : Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus. May 6, 2017 451
FDA approves clinical trial of burn cell therapy. Apr 24, 2017 448
FDA approves company's burn clinical trial related to federal contract. Apr 17, 2017 448
FDA approves company's burn clinical trial related to federal contract. Apr 17, 2017 447
Puma Biotechnology Presents Trial Results for PB272 in ERBB2 Mutant, HER2 Non-Amplified, Metastatic Cancer. Apr 4, 2017 519
Infectex's Pulmonary Tuberculosis drug achieves Positive Phase 2b-3 Clinical Trial Results. Clinical report Mar 28, 2017 161
Infectex's Pulmonary Tuberculosis drug achieves Positive Phase 2b-3 Clinical Trial Results. Clinical report Mar 28, 2017 157
Treatment for heart attack proven safe in phase 1/2 trial. Mar 27, 2017 391
MediGene announces details of first clinical trial in TCR cancer immunotherapy. Mar 23, 2017 265
MediGene announces details of first clinical trial in TCR cancer immunotherapy. Mar 23, 2017 261
US FDA Accepts Asana BioSciences IND Application for Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis. Clinical report Mar 20, 2017 223
Top-Line phase 1/2 results of treatment for heart attack. Clinical report Mar 20, 2017 382
Top-line Phase 1/2 results Of treatment for heart attack. Clinical report Mar 20, 2017 382
$12.2 Million from CIRM supports Phase 2 trial of diabetes treatment. Mar 13, 2017 341
TiGenix announces topline data for Phase III Crohn's disease study. Clinical report Mar 9, 2017 283
TiGenix announces topline data for Phase III Crohn's disease study. Clinical report Mar 9, 2017 279
$12.2M grant from CIRM supports phase 2 trial of diabetes treatment. Mar 6, 2017 340
$12.2M grant from CIRM supports phase 2 trial of diabetes treatment. Mar 6, 2017 340
Roche's Genentech to begin new Phase III trial of Alzheimer's drug. Mar 1, 2017 271
Roche's Genentech to begin new Phase III trial of Alzheimer's drug. Mar 1, 2017 267
Exelixis Presents Phase 1 Trial Results for Cabozantinib, Nivolumab Combo in Genitourinary Tumors. Feb 22, 2017 288
First patient enrolled in Phase 1b/2a trial of severe sepsis treatment. Feb 6, 2017 443
Ablynx files for caplacizumab approval amidst phase III trials. Feb 6, 2017 229
Ablynx files for caplacizumab approval amidst phase III trials. Feb 6, 2017 225
First patient enrolled in phase 1b/2a trial of severe sepsis treatment. Feb 6, 2017 451
Seattle Biotech Neovia Starts Clinical Trial for Immunotherapy Enhancing Cancer Drug. Jan 30, 2017 305
MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. Jan 12, 2017 176
MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. Jan 12, 2017 172
Agricultural biotechnology is much more than herbicide-tolerant crops. Miller, Henry I.; Wager, Robert Essay Jan 1, 2017 2419
R&D spending & success: key trends, issues & solutions. Rao, Sanjay Kumar Jan 1, 2017 3526
United States : ACADIA Pharmaceuticals initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients with Negative Symptoms of Schizophrenia. Nov 18, 2016 201
Cytori wins US FDA's orphan drug designation for ECCS-50 for scleroderma. Nov 15, 2016 233
Cytori wins US FDA's orphan drug designation for ECCS-50 for scleroderma. Nov 15, 2016 229
United States : Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX) in Combination with carfilzo0mib. Nov 11, 2016 626
Assembly Biosciences begins Phase 1 clinical trial of ABI-H0731 for treating chronic hepatitis B virus infection. Nov 10, 2016 243
Assembly Biosciences begins Phase 1 clinical trial of ABI-H0731 for treating chronic hepatitis B virus infection. Nov 10, 2016 239
United States : Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS in Frontline Mature T-cell Lymphoma. Nov 9, 2016 574
Japan : Seattle Genetics and Takeda complete enrollment of phase 3 ECHELON-2 clinical trial evaluating ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell Lymphoma. Nov 9, 2016 578
Company to work with Hadassah Medical Center on ALS clinical trial. Nov 7, 2016 370

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters